Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Amphastar Pharmaceuticals (AMPH) Acquisitions (2016)

Amphastar Pharmaceuticals has reported Acquisitions over the past 3 years, most recently at $3.4 million for Q4 2016.

Quarterly results put Acquisitions at $3.4 million for Q4 2016, down 2.86% from a year ago — trailing twelve months through Dec 2016 was $11.7 million (changed N/A YoY), and the annual figure for FY2016 was $12.5 million, up 256.03%.
Acquisitions for Q4 2016 was $3.4 million at Amphastar Pharmaceuticals, up from $761000.0 in the prior quarter.
Over the last five years, Acquisitions for AMPH hit a ceiling of $6.0 million in Q4 2014 and a floor of $761000.0 in Q2 2016.
Median Acquisitions over the past 3 years was $3.5 million (2015), compared with a mean of $3.5 million.
Biggest five-year swings in Acquisitions: crashed 41.67% in 2015 and later decreased 2.86% in 2016.
Amphastar Pharmaceuticals' Acquisitions stood at $6.0 million in 2014, then tumbled by 41.67% to $3.5 million in 2015, then fell by 2.86% to $3.4 million in 2016.
The last three reported values for Acquisitions were $3.4 million (Q4 2016), $761000.0 (Q2 2016), and $4.0 million (Q1 2016) per Business Quant data.